UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other jurisdic ...

Royalty Pharma plc (NASDAQ:RPRX) Q3 2021 Results Conference Call November 10, 2021 8:00 AM ET Company Participants Pablo Legorreta – Founder and Chief Executive Officer Chris Hite – Vice Chairman Terry Coyne – EVP, Chief Financial Officer Jim Reddoch – EVP, Co-Head of Research and Investments and Chief Scientific Officer Marshall Urist – EVP, Co-Head of Research and Investments George Grofik – SVP, Head of Investor Relations and Communications Conference Call Participants Chris Schott – J.P. Morgan Andrew B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant h ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2021 Earnings Conference Call August 11, 2021 8:00 AM ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder & CEO Jim Reddoch - EVP, Co-Head Research & Investments & CSO Marshall Urist - EVP & Co-Head, Research & Investments Terry Coyne - EVP & CFO Chris Hite - Vice Chairman Conference Call Participants Chris Schott - J.P. Morgan Bill Maughan - Bank of America Steve Scala - Cowen Terence Flynn - Goldman Sachs Umer Raffat - Everc ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q2 2021 Financial Results August 11, 2021 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) England and Wales 98-1535773 (I ...

R □ YALTY PHARMA Royalty Pharma plc MorphoSys Transaction Advancing innovation with complete funding solutions June 2, 2021 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Sta ...

ROYALTY PHARMA UBS Global Healthcare Conference Terrance Coyne, EVP, Chief Financial Officer Marshall Urist, EVP, Co-Head of Research & Investments May 24, 2021 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all o ...

ROYALTY PHARMA 7th Annual Truist Securities 2021 Life Sciences Summit Terrance Coyne, EVP, Chief Financial Officer Christopher Hite, EVP, Vice Chairman Jim Reddoch, EVP, Co-Head Research & Investments and Chief Scientific Officer May 20, 2021 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. Th ...

ROYALTY PHARMA Bank of America 2021 Healthcare Conference Terrance Coyne, EVP, Chief Financial Officer Marshall Urist, EVP, Co-Head Research & Investments May 12, 2021 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contai ...